Fulgent Genetics, Inc.
For the period ended Jun 1, 2026. Filed Jun 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 1, 2026 · Filed Jun 2, 2026
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2026
FULGENT GENETICS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-37894 | 81-2621304 |
|---|---|---|
| (State or other jurisdiction ofincorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 4399 Santa Anita AvenueEl Monte, California | 91731 |
|---|---|
| (Address of Principal Executive Offices) | (Zip Code) |
(626)350-0537
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | FLGT | The Nasdaq Stock Market (Nasdaq Global Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 1, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, previously released on May 21, 2026. A copy of the Company’s press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K.
(d) Exhibits.
| ExhibitNo. | Description |
| 99.1 | Press Release dated June 1, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 1, 2026 | FULGENT GENETICS, INC. | |
|---|---|---|
| By: | /s/ Paul Kim | |
| Name: | Paul Kim | |
| Title: | Chief Financial Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.